Abstract
More than 2 million people have died from COVID-19, caused by SARS-CoV-2.1 In an unprecedented effort to develop vaccines to control the COVID-19 pandemic, mRNA, protein subunit, and viral vector-based vaccines have been developed within an extraordinarily swift timeframe. However, the efficacy of these vaccines (ie, their ability to reduce the incidence of severe disease and death from COVID-19) can vary considerably. For example, among 43 448 adults, the efficacy of the mRNA-based COVID-19 vaccine produced by Pfizer and BioNTech ranged between 29·5% and 68·4% against symptomatic COVID-19 after the first dose, and between 90·3 and 97·6% after the second dose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
